TherapeuticsMD
TXMD
134 hedge funds and large institutions have $867M invested in TherapeuticsMD in 2017 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 8 closing their positions.
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
15% more funds holding
Funds holding: 117 → 134 (+17)
6% more capital invested
Capital invested by funds: $821M → $867M (+$45.4M)
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
0.01% less ownership
Funds ownership: 1.53% → 1.52% (-0.01%)
16% less call options, than puts
Call options by funds: $1.89M | Put options by funds: $2.27M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$36.7M |
| 2 |
Bank of New York Mellon
New York
|
+$17.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.3M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.19M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.4M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$4.31M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.76M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$3.26M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.8M |
TXMD Hedge Fund Activity: Q3 2017 in Review
134 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2017, worth a combined $867M — up 5.5% from $821M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TXMD positions and 8 closed out — a net gain of 19 holders — while 43 added to existing stakes and 40 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $36.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $25.4M.
- 134 institutional investors held TherapeuticsMD (TXMD) as of Q3 2017, up from 117 in Q2 2017.
- Funds reported $867M of TherapeuticsMD stock for Q3 2017, up 5.5% quarter-over-quarter.
- 27 funds opened new TherapeuticsMD positions in Q3 2017 and 8 closed out, a net change of +19 holders.
- The largest TherapeuticsMD buyer in Q3 2017 was JP Morgan Chase, an estimated $36.7M added.
- The largest TherapeuticsMD seller in Q3 2017 was T. Rowe Price Associates, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2017.